Related Experiment Video

Updated: Dec 3, 2025

Assessment of Child Anthropometry in a Large Epidemiologic Study
09:36

Assessment of Child Anthropometry in a Large Epidemiologic Study

Published on: February 2, 2017

27.6K

Exploring Potentially Modifiable Factors That Influence Treatment Non-Adherence Amongst Pediatric Growth Hormone

Selina Graham1, Vivian Auyeung1, John Weinman1

  • 1School of Cancer and Pharmaceutical Sciences, King's College London, London, UK.

Patient Preference and Adherence
|October 29, 2020
PubMed

Insights

Pediatric non-adherence to growth hormone treatment is common. This study identifies modifiable factors like device burdens and logistical issues that impact adherence for children with growth hormone deficiency.

Area of Science:

  • Pediatric Endocrinology
  • Qualitative Health Research

Background:

  • High rates of non-adherence (up to 71%) to growth hormone treatment in children.
  • Understanding parent/caregiver experiences is crucial for addressing pediatric non-adherence.
  • This study is the first to examine modifiable factors influencing adherence to recombinant human growth hormone (rhGH) treatment.

Purpose of the Study:

  • To explore parents'/caregivers' perceptions and experiences regarding their child's growth hormone deficiency and treatment.
  • To identify potentially modifiable factors influencing non-adherence to rhGH therapy.
  • To understand the parent/caregiver relationship with healthcare professionals.

Main Methods:

  • Conducted 14 semi-structured telephone interviews with parents/caregivers.
  • Employed thematic analysis and narrative synthesis.
  • Utilized a qualitative research approach (Braun and Clarke, 2006).

Main Results:

  • Identified four key themes influencing non-adherence: Device Burdens, Treatment Considerations, Logistical Interferences, and Interpersonal Influences.
  • These themes highlight a range of factors that can be modified to improve treatment adherence.
  • Parental perceptions and experiences are central to understanding adherence challenges.

Conclusions:

  • Exploratory findings reveal numerous modifiable factors affecting rhGH treatment use in children.
  • Results can inform the development of targeted interventions to improve adherence.
  • Optimizing growth hormone treatment requires supporting children and families within endocrine clinical practice.
Abstract

Keywords:
GHDadherencecaregivergrowth hormone deficiencyparentqualitativerecombinant human growth hormone treatmentrhGH

More Related Videos

Treatment Model for Young Patients with Psychogenic Erectile Dysfunction and Resultant Infertility04:22

Treatment Model for Young Patients with Psychogenic Erectile Dysfunction and Resultant Infertility

Published on: May 30, 2025

577
Home-Based Monitor for Gait and Activity Analysis07:24

Home-Based Monitor for Gait and Activity Analysis

Published on: August 8, 2019

7.1K

Related Concept Videos

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
132
Therapeutic Drug Monitoring: Affecting Factors01:29

Therapeutic Drug Monitoring: Affecting Factors

Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring specific drug levels in a patient's blood or body tissues to manage and optimize therapy. TDM is crucial for drugs with narrow therapeutic windows, like warfarin and phenytoin, where incorrect doses can lead to treatment failure or severe side effects. This monitoring ensures the dosage administered is within a safe and effective range. The factors affecting therapeutic drug monitoring include:Patient-Specific Factors:a.
102
Factors Affecting Protein-Drug Binding: Patient-Related Factors01:29

Factors Affecting Protein-Drug Binding: Patient-Related Factors

Protein-drug binding, a pivotal aspect of pharmacokinetics, is subject to considerable variability influenced by an array of patient-related factors. The intricate interplay of age, individual differences, and pathological conditions significantly impact the binding dynamics and subsequent pharmacological effects.
Age stands as a key determinant in protein-drug binding. Neonates, characterized by low albumin content, experience heightened concentrations of unbound drugs such as phenytoin and...
203
Nature and Nurture01:10

Nature and Nurture

Many human characteristics, like height, are shaped by both nature—in other words, by our genes—and by nurture, or our environment. For example, chronic stress during childhood inhibits the production of growth hormones and consequently reduces bone growth and height. Scientists estimate that 70-90% of variation in height is due to genetic differences among individuals, and 10-30% of variation in height is due to differences in the environments that individuals experience,...
21.8K
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
124
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
101